Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 4, 2024

Low-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMichèlle RosenzwajgMACOM (United States)AGAlina GherasimItasca Consultants (France)FDF DietschHôpital Civil, Strasbourg

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rosenzwajg et al. (2024) studied this question.

synapsesocial.com/papers/68e5969ab6db643587531bcbhttps://doi.org/10.1101/2024.09.04.24312986
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells2004 · 1,055 citations
  2. 2Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease2011 · 1,140 citations
  3. 3Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial2015 · 241 citations
  4. 4Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial2018 · 417 citations
  5. 5Systemic IL ‐2/anti‐ IL ‐2Ab complex combined with sublingual immunotherapy suppresses experimental food allergy in mice through induction of mucosal regulatory T cells2018 · 40 citations